TY - JOUR
T1 - Molecular pathways
T2 - The eIF4F translation initiation complex-newopportunities for cancer treatment
AU - Malka-Mahieu, Hélène
AU - Newman, Michelle
AU - Désaubry, Laurent
AU - Robert, Caroline
AU - Vagner, Stéphan
N1 - Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - The eIF4F complex regulates the cap-dependent mRNA translation process. It is becoming increasingly evident that aberrant activity of this complex is observed in many cancers, leading to the selective synthesis of proteins involved in tumor growth and metastasis. The selective translation of cellular mRNAs controlled by this complex also contributes to resistance to cancer treatments, and downregulation of the eIF4F complex components can restore sensitivity to various cancer therapies. Here, we review the contribution of the eIF4F complex to tumorigenesis, with a focus on its role in chemoresistance as well as the promising use of new smallmolecule inhibitors of the complex, including flavaglines/rocaglates, hippuristanol, and pateamine A.
AB - The eIF4F complex regulates the cap-dependent mRNA translation process. It is becoming increasingly evident that aberrant activity of this complex is observed in many cancers, leading to the selective synthesis of proteins involved in tumor growth and metastasis. The selective translation of cellular mRNAs controlled by this complex also contributes to resistance to cancer treatments, and downregulation of the eIF4F complex components can restore sensitivity to various cancer therapies. Here, we review the contribution of the eIF4F complex to tumorigenesis, with a focus on its role in chemoresistance as well as the promising use of new smallmolecule inhibitors of the complex, including flavaglines/rocaglates, hippuristanol, and pateamine A.
UR - http://www.scopus.com/inward/record.url?scp=85010469878&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-14-2362
DO - 10.1158/1078-0432.CCR-14-2362
M3 - Review article
C2 - 27789529
AN - SCOPUS:85010469878
SN - 1078-0432
VL - 23
SP - 21
EP - 25
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 1
ER -